Literature DB >> 18845914

Effect of hemodialysis on hepatic cytochrome P450 functional expression.

Josée Michaud1, Thomas D Nolin, Judith Naud, Mélina Dani, Jean-Philippe Lafrance, Francois A Leblond, Jonathan Himmelfarb, Vincent Pichette.   

Abstract

Cytochrome P450 (CYP) functional expression is reduced in uremia and normalized after restoration of kidney function via transplantation. The aim of this study was to evaluate the effect of conventional hemodialysis on the functional expression of CYP1A, 2C, and 3A. We also investigated the role of nuclear factor-kappaB (NF-kappaB) in CYP regulation during uremia. Primary cultures of normal rat hepatocytes were incubated with serum obtained from end-stage renal disease patients pre- and post-hemodialysis and healthy control subjects, in the presence and absence of the NF-kappaB inhibitor andrographolide. Uremic pre-hemodialysis serum caused significant reductions (P<0.01) in CYP1A (44%), 2C (27%), and 3A (35%) protein expression compared to control serum, while dialyzed serum (i.e., obtained immediately post-hemodialysis) had no effect. CYP1A2, 2C11, and 3A2 mRNA expression, as well as CYP3A activity, were similarly impacted by uremic serum and were improved to >80% of control values after hemodialysis. NF-kappaB inhibition nearly eliminated the effect of uremic serum on CYP functional expression. This is the first study to demonstrate that conventional hemodialysis acutely improves altered CYP functional expression observed in rat hepatocytes incubated with uremic human serum.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18845914     DOI: 10.1254/jphs.08042fp

Source DB:  PubMed          Journal:  J Pharmacol Sci        ISSN: 1347-8613            Impact factor:   3.337


  20 in total

Review 1.  Consequences of renal failure on non-renal clearance of drugs.

Authors:  Laure Lalande; Bruno Charpiat; Gilles Leboucher; Michel Tod
Journal:  Clin Pharmacokinet       Date:  2014-06       Impact factor: 6.447

2.  Effects of uremic toxins on transport and metabolism of different biopharmaceutics drug disposition classification system xenobiotics.

Authors:  Maribel Reyes; Leslie Z Benet
Journal:  J Pharm Sci       Date:  2011-05-26       Impact factor: 3.534

3.  Sources of Interindividual Variability.

Authors:  Yvonne S Lin; Kenneth E Thummel; Brice D Thompson; Rheem A Totah; Christi W Cho
Journal:  Methods Mol Biol       Date:  2021

4.  Significant increase in plasma 4β-hydroxycholesterol concentration in patients after kidney transplantation.

Authors:  Yosuke Suzuki; Hiroki Itoh; Fuminori Sato; Kanako Kawasaki; Yukie Sato; Takashi Fujioka; Yuhki Sato; Keiko Ohno; Hiromitsu Mimata; Satoshi Kishino
Journal:  J Lipid Res       Date:  2013-07-04       Impact factor: 5.922

5.  Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles.

Authors:  Paola Di Gion; Friederike Kanefendt; Andreas Lindauer; Matthias Scheffler; Oxana Doroshyenko; Uwe Fuhr; Jürgen Wolf; Ulrich Jaehde
Journal:  Clin Pharmacokinet       Date:  2011-09       Impact factor: 6.447

6.  CYP3A5 polymorphism affects the increase in CYP3A activity after living kidney transplantation in patients with end stage renal disease.

Authors:  Yosuke Suzuki; Takashi Fujioka; Fuminori Sato; Kunihiro Matsumoto; Nanako Muraya; Ryota Tanaka; Yuhki Sato; Keiko Ohno; Hiromitsu Mimata; Satoshi Kishino; Hiroki Itoh
Journal:  Br J Clin Pharmacol       Date:  2015-10-03       Impact factor: 4.335

Review 7.  Antimicrobial dosing in acute renal replacement.

Authors:  William H Fissell
Journal:  Adv Chronic Kidney Dis       Date:  2013-01       Impact factor: 3.620

Review 8.  Impaired vitamin D metabolism in CKD.

Authors:  Cortney Bosworth; Ian H de Boer
Journal:  Semin Nephrol       Date:  2013-03       Impact factor: 5.299

Review 9.  Pharmacokinetics and dosage adjustment in patients with renal dysfunction.

Authors:  Roger K Verbeeck; Flora T Musuamba
Journal:  Eur J Clin Pharmacol       Date:  2009-06-20       Impact factor: 2.953

Review 10.  Uraemic syndrome of chronic kidney disease: altered remote sensing and signalling.

Authors:  Sanjay K Nigam; Kevin T Bush
Journal:  Nat Rev Nephrol       Date:  2019-05       Impact factor: 28.314

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.